EFFICACY AND SAFETY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB AS FRONTLINE TREATMENT FOR INDOLENT CLINICAL FORMS OF MANTLE CELL LYMPHOMA. RESULTS OF THE GELTAMO IMCL‐2015 STUDY | Publicación